# EDGAR Filing Document

**Accession Number:** 0001719406
**File Stem:** 0001437749-25-036452
**Filing Date:** 2025-11
**Character Count:** 9552
**Document Hash:** 30ea8a16bdce2ab23ac88169d8cec991
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-036452.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001437749-25-036452

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Changes in Registrant's Certifying Accountant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NRX Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001719406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822844431
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38302
- **FILM NUMBER:** 251530826

**BUSINESS ADDRESS:**
- **STREET 1:** 1201 ORANGE STREET
- **STREET 2:** SUITE 600
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 484-254-6134

**MAIL ADDRESS:**
- **STREET 1:** 1201 ORANGE STREET
- **STREET 2:** SUITE 600
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Big Rock Partners Acquisition Corp.
- **DATE OF NAME CHANGE:** 20171012

?xml version='1.0' encoding='ASCII'? nrxp20251125_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 20, 2025**

---

| |
|:---|
| **NRX PHARMACEUTICALS, INC.** |
| **(Exact name of registrant as specified in its charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38302** | **82-2844431** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

---

| | |
|:---|:---|
| **1201 Orange Street, Suite 600**<br> **Wilmington, Delaware**  | **19801** |
| **(Address of principal executive offices)** | **(Zip Code)**  |

---

**<u>(484)</u><u>254-6134</u>**

**(Registrant**'**s telephone number, including area code)**&nbsp;&nbsp;&nbsp;&nbsp;

**<u>Not applicable</u>**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, par value $0.001 per share | NRXP | The Nasdaq Stock Market LLC |
| Warrants to purchase one share of Common Stock | NRXPW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 4.01 Changes in Registrant**'**s Certifying Accountant.**

***Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm***

On November 20, 2025, the audit committee of the board of directors (the "Audit Committee") of NRx Pharmaceuticals, Inc. (the "Corporation") approved the engagement of Weinberg & Company P.A. ("Weinberg") as the Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc. ("HOPE"), a subsidiary of the Corporation. During the Corporation's two most recent fiscal years and the subsequent interim period through September 30, 2025, neither the Corporation, nor anyone on its behalf, consulted Weinberg regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Corporation's financial statements, and neither a written report nor oral advice was provided to the Corporation that Weinberg concluded was an important factor considered by the Corporation in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K.

For the reason stated above, on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A. ("Salberg") as the Corporation's independent registered public accounting firm.

Salberg's audit reports on the Corporation's consolidated financial statements for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the audit opinion contained an explanatory paragraph regarding the Company's ability to continue as a going concern.

During the Corporation's two most recent fiscal years, which ended December 31, 2024 and December 31, 2023, and the subsequent interim period through September 30, 2025, (i) there were no "disagreements" (within the meaning set forth in Item 304(a)(1)(iv) of Regulation S-K) between the Corporation and Salberg on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Salberg's satisfaction, would have caused Salberg to make reference to the subject matter of the disagreements in connection with their reports; and (ii) there were no "reportable events" (within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K).

In accordance with Item 304(a)(3) of Regulation S-K, the Corporation provided Salberg with a copy of this Current Report on Form 8-K and requested that Salberg furnish the Corporation with a letter addressed to the United States Securities and Exchange Commission stating whether Salberg agrees with the above statements of the Corporation herein and, if not, stating the respects in which it does not agree. Salberg furnished the requested letter, stating its agreement with such statements, and a copy is filed as Exhibit 16.1 to this Current Report on Form 8-K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

***(d) Exhibits***

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 16.1\* | [Letter from Salberg & Company P.A. to the SEC dated November 25, 2025.](ex_893504.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

\* Filed herewith

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | NRx Pharmaceuticals, Inc. | NRx Pharmaceuticals, Inc. |
| Date: November 26, 2025 | By: | */s/ Jonathan Javitt* |
|  | Name: | Jonathan Javitt |
|  | Its: | Interim Chief Executive Officer |

---

## Exhibit 16.1

**Exhibit 16.1**

![logo0.jpg](logo0.jpg)

November 25, 2025

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Re: NRX Pharmaceuticals, Inc.

File Reference No. 001-38302

We were previously the independent registered public accounting firm for NRX Pharmaceuticals, Inc. and under the date of March 14, 2025, we reported on the consolidated financial statements of NRX Pharmaceuticals, Inc. and Subsidiaries, as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024.

On November 24, 2025, we were dismissed as the independent registered public accounting firm. We have read NRX Pharmaceuticals, Inc.'s disclosures included in Item 4.01 "Changes in Registrant's Certifying Accountant" on NRX Pharmaceuticals, Inc.'s Form 8-K dated November 26, 2025 to be filed with the Securities and Exchange Commission and we agree with such statements as they pertain to Salberg & Company, P.A.

Very truly yours,

![sig0.jpg](sig0.jpg)

SALBERG & COMPANY, P.A.

Certified Public Accountants and Consultants